Metabolomics and lipidomics analyses by H-1 nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis

Autor(es):Mostrar menos -

Tasic, Ljubica ; Pontes, Joao G. M. ; Carvalho, Michelle S. ; Cruz, Guilherme ; Dal Mas, Carolines ; Sethi, Sumit ; Pedrini, Mariana ; Rizzo, Lucas B. ; Zeni-Graiff, Maiara ; Asevedo, Elson ; Lacerda, Acioly L. T. ; Bressan, Rodrigo A. ; Poppi, Ronei Jesus ; Brietzke, Elisa ; Hayashi, Mirian A. F.

• Tipo de documento: Artigo Científico
• Fonte: SCHIZOPHRENIA RESEARCH; v. 185, p. 182-189, JUL 2017.
• Citações Web of Science: 7

Resumo

Using H-1 NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabolic differences between schizophrenia patients (SCZ) compared to healthy controls (HCs). HCs and SCZ patients underwent clinical interview using the Structured Clinical Interview for DSM Disorders (SCID). SCZ patients were further assessed by Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, Global Assessment of Functioning Scale (GAF), and Clinical Global Impressions Scale (CGI). Using the principal component analysis (PCA) and supervised partial least-squares discriminate analysis (PLS-DA) in obtained NMR data, a clear group separation between HCs and SCZ patients was achieved. Interestingly, all metabolite compounds identified as exclusively present in the SCZ group, except for the gamma-aminobutyric acid (GABA), were never previously associated with mental disorders. Although the initial perception of an absence of obvious biological link among the different key molecules exclusively observed in each group, and no identification of any specific pathway yet, the present work represents an important contribution for the identification of potential biomarkers to inform diagnosis, as it was possible to completely separate the affected SCZ patients from HCs, with no outliers or exceptions. In addition, the data presented here reinforced the role of the modulation of glycolysis pathway and the loss of GABA intemeuron/hyperglutamate hypothesis in SCZ. (C) 2016 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 13/13392-4 - Avaliação do uso dos análogos da crotamina em diagnóstico ou terapia
• Beneficiário: Mirian Akemi Furuie Hayashi
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/18938-8 - Ressonância magnética nuclear aplicada em análises metabolômicas de pacientes e em modelos animais para os transtornos mentais graves
• Beneficiário: Ljubica Tasic
• Modalidade de apoio: Auxílio à Pesquisa - Regular